Cryoprecipitate for the correction of coagulopathy associated with liver disease

Anaesthesia and Intensive Care

Volumn 31, Issue 4, 2003, Pages 357-361

  French, C J ^a   Bellomo, R ^b   Angus, P ^b  

^a WESTERN HOSPITAL   (Australia)

^b AUSTIN HEALTH   (Australia)

Author keywords

Blood: component, transfusion; Coagulation: protein disorders; Cryoprecipitate: coagulum

Indexed keywords

BATROXOBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD DERIVATIVE; D DIMER; FIBRINOGEN; FIBRONECTIN; FRESH FROZEN PLASMA; THROMBOPLASTIN; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSSOVER PROCEDURE; CRYOPRECIPITATE; DISEASE ASSOCIATION; HUMAN; INTERMETHOD COMPARISON; INTERNATIONAL STANDARD UNIT; LIVER DISEASE; LIVER FAILURE; LUNG EDEMA; PARTIAL THROMBOPLASTIN TIME; RETROSPECTIVE STUDY; RISK ASSESSMENT; TIME; TREATMENT OUTCOME;

EID: 0042424534     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x0303100403     Document Type: Article

References (17)

1. Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets. Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists. JAMA 1994; 271:777-781.
2. Consensus Conference. Fresh Frozen Plasma. Indications and Risks. JAMA 1985; 253:551-553.
3. Oberman HA. Indications and monitoring of use of fresh frozen plasma as a hemostatic agent. Curr Stud Hematol Blood Transfus 1986; 53:125-132.
4. Kelly DA, Summerfield JA. Hemostasis in liver disease. Semin Liver Dis 1987; 7:182-191.
5. Kellner SV. Blood Products Issue Policies. 1994. Melbourne, Australian Red Cross.
6. Mallet SV, Cox DJA. Thromboelastography. Br J Anaesth 1992; 307-313.
7. Humphries JE. Transfusion therapy in acquired coagulopathies. Hematol Oncol Clin North Am 1994; 8:1181-1201.
8. Poon MC. Cryoprecipitate: uses and alternatives. Transfus Med Rev 1993; 7:180-192.
9. Mammen EF. Coagulation abnormalities in liver disease. Hematol Oncol Clin North Am 1992; 6:1247-1257.
10. Mammen EF. Coagulation defects in liver disease. Med Clin North Am 1994; 78:545-554.
11. Mammen EF. Coagulopathies of liver disease. Clin Lab Med 1994; 14:769-780.
12. Gazzard BG, Henderson JM, Williams R. The use of fresh frozen plasma or a concentrate of factor IX as replacement therapy before liver biopsy. Gut 1975; 16:621-625.
13. Mannucci PM, Franchi F, and Dioguardi N. Correction of abnormal coagulation in chronic liver disease by combined use of fresh-frozen plasma and prothrombin complex concentrates. Lancet 1976; 2:542-545.
14. Spector I, Corn M, Ticktin HE. Effect of plasma transfusions on the prothrombin time and clotting factors in liver disease. N Engl J Med 1966; 275:1032-1037.
15. Gazzard BG, Lewis ML, Ash G., Rizza CR, Bidwell E, Williams R. Coagulation factor concentrate in the treatment of the haemorrhagic diathesis of fulminant hepatic failure. Gut 1974; 15:993-998.
16. Green G, Dymock IW, Poller L, Thomson JM. Use of factor-VII-rich prothrombin complex concentrate in liver disease. Lancet 1975; 1:1311-1314.
17. Lusher JM. Thrombogenicity associated with factor IX complex concentrates. Semin Hematol 1991; 28 suppl 6:3-5.